Heparin Sodium Injection Shortage: Supply Updates and Manufacturer Status
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
Heparin Sodium Injection is currently experiencing supply disruptions, with several manufacturers reporting limited availability or discontinued products while others maintain stock.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Heparin Sodium Injection) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
Heparin Sodium Injection, a medication used in the therapeutic category of hematology, is currently listed as in shortage. This includes products labeled as Heparin Sodium and Heparin Sodium in Sodium Chloride. The shortage affects various presentations of the injection dosage form. This status was first posted on November 14, 2017, and was most recently updated on February 5, 2026.
Which Manufacturers Are Affected
Several manufacturers are involved in the production of Heparin Sodium Injection, with varying levels of availability:
B. Braun Medical Inc. (800-227-2862):
- Available: Heparin Sodium 1,000 Units In Sodium Chloride 0.9% (NDC 0264-9872-10)
- Available: Heparin Sodium 2,000 Units in Sodium Chloride 0.9% (NDC 0264-9872-00)
Baxter Healthcare (888-229-0001):
- Available: Heparin Sodium In Sodium Chloride (NDC 0338-0433-04)
- Unavailable: Heparin Sodium In Sodium Chloride (NDC 0338-0424-18). Note: This product has been discontinued and replaced by Product Code 2B0953.
- Unavailable: Heparin Sodium In Sodium Chloride (NDC 0338-0431-03). Estimated recovery is March 2026.
Fresenius Kabi USA, LLC (888-386-1300):
- Available: Heparin Sodium (NDC 63323-519-77). The manufacturer suggests checking wholesalers for inventory.
- Unavailable: Heparin Sodium (NDC 63323-519-10). The next release is expected in February 2026. Check wholesalers for current inventory.
Why There's a Shortage
No specific reason for the overall shortage was provided in the source data. However, individual manufacturer notes indicate that certain presentations have been discontinued or are facing temporary supply gaps with estimated recovery dates in early 2026.
What Patients Should Do
If you or a loved one relies on Heparin Sodium Injection, please consider the following steps:
- Consult your healthcare provider: Discuss your treatment plan and any concerns regarding medication availability.
- Speak with your pharmacist: Pharmacists can check current inventory across different wholesalers and may have information on which specific presentations are currently in stock.
- Contact manufacturers: You may use the contact information provided above to inquire about the most up-to-date availability for specific NDCs.
Disclaimer: Patients should always consult their healthcare provider for medical advice and before making any changes to their medication or treatment regimen.
Source
Information provided by the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category